Next-generation sequencing identifies a novel ELAVL1–TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208

Adriana E. TronOncology iMed, AstraZeneca, Waltham, MA, USA; Correspondence[email protected]

Erika K. KeetonOncology iMed, AstraZeneca, Waltham, MA, USA; ;N-of-One, Inc, Lexington, MA, USA;

Minwei YeOncology iMed, AstraZeneca, Waltham, MA, USA;

Matias Casas-SelvesOncology iMed, AstraZeneca, Waltham, MA, USA; ;Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Canada;

Huawei ChenOncology iMed, AstraZeneca, Waltham, MA, USA;

Keith S. DillmanOncology iMed, AstraZeneca, Waltham, MA, USA;

Rosemary E. GaleDepartment of Haematology, University College London Cancer Institute, London, UK;

Chloe StengelDepartment of Haematology, University College London Cancer Institute, London, UK;

Michael ZindaOncology iMed, AstraZeneca, Waltham, MA, USA;

David C. LinchDepartment of Haematology, University College London Cancer Institute, London, UK;

Zhongwu LaiOncology iMed, AstraZeneca, Waltham, MA, USA;

Asim KhwajaDepartment of Haematology, University College London Cancer Institute, London, UK;

Dennis HuszarOncology iMed, AstraZeneca, Waltham, MA, USA; ;Oncology Drug Discover Unit, Takeda Pharmaceuticals International Co, Cambridge, MA, USA

References